Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07328230 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Idiopathic hyperaldosteronism (IHA) represents about 65% of primary hyperaldosteronism cases. Although mineralocorticoid receptor antagonists (MRAs) are the standard first-line treatment, they are often limited by adverse effects. Superselective adrenal artery embolization (SAAE) has been utilized for IHA over the last decade, yet comparative studies against MRAs are lacking. The objective of this study is to compare the safety and efficacy of SAAE and MRA to determine the feasibility of SAAE in treating IHA.
Trial Details
NCT Number NCT07328230
Lead Sponsor Chinese Academy of Medical Sciences, Fuwai Hospital
Collaborators: Second Affiliated Hospital of Nanchang University, First Affiliated Hospital of Chengdu Medical College
Conditions
(from sponsor)		 Idiopathic Hyperaldosteronism, Hyperaldosteronism
Related terms Hyperaldosteronism, Hypertension
Enrollment 172 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov